SAB Biotherapeutics (SABS) Net Margin (2021 - 2024)
SAB Biotherapeutics (SABS) reported Net Margin of 9934.52% for Q4 2024, down 244077.0% on a YoY basis from N/an in Q1 2024, and down 256.37% quarter-over-quarter from 2787.69% in Q2 2024.
SAB Biotherapeutics (SABS) Net Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics has reported Net Margin for 4 years, with the latest figure at 9934.52% in Q4 2024.
- For the quarter ending Q4 2024, Net Margin fell 244077.0% year-over-year to 9934.52%; the trailing twelve-month figure through Dec 2024 stood at 2579.03% (down 69453.0% YoY), and the FY2024 full-year result was 2579.03%, down 69453.0% from the prior year.
- Net Margin for Q4 2024 stood at 9934.52%, down from 2787.69% in the prior quarter.
- The five-year high for Net Margin was 8.35% in Q1 2022, with the low at 9934.52% in Q4 2024.
- Historically, Net Margin has averaged 2082.04% across 4 years, with a median of 364.42% in 2022.
- Annual changes were most pronounced in 2023 — Net Margin tumbled 797092 bps — and 2024, when it surged 525843 bps.
- SAB Biotherapeutics' Net Margin stood at 104.46% in 2021, then sank by 249 bps to 364.42% in 2022, then sank by 1956 bps to 7493.75% in 2023, then tumbled by 33 bps to 9934.52% in 2024.
- The last three Net Margin figures came in at 9934.52% (Q4 2024), 2787.69% (Q2 2024), and 532.06% (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -9,934.52% |
| Jun 30, 2024 | -2,787.69% |
| Mar 31, 2024 | -532.06% |
| Dec 31, 2023 | -7,493.75% |
| Sep 30, 2023 | -402.59% |
| Jun 30, 2023 | -8,046.13% |
| Mar 31, 2023 | -1,265.50% |
| Dec 31, 2022 | -364.42% |
| Sep 30, 2022 | -197.12% |
| Jun 30, 2022 | -75.21% |
| Mar 31, 2022 | 8.35% |
| Dec 31, 2021 | -104.46% |
| Sep 30, 2021 | -27.66% |
| Jun 30, 2021 | -16.15% |
| Mar 31, 2021 | 8.33% |